| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.32 - $47.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
201,796 |
329,048 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$14,896,079 |
| Total People Sold |
1 |
1 |
15 |
17 |
| Total Sell Transactions |
3 |
3 |
36 |
63 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greene William |
10% Owner |
– – • |
2011-02-08 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,200,247 |
2,293,227 |
|
- |
|
| Evnin Luke |
Director |
– • • |
2011-02-08 |
4/A |
B |
$7.00 |
$3,749,998 |
I/I |
535,714 |
2,828,941 |
2.25 |
- |
|
| Evnin Luke |
Director |
– • • |
2011-02-08 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,200,247 |
2,293,227 |
|
- |
|
| Gadicke Ansbert |
10% Owner |
– – • |
2011-02-08 |
4/A |
B |
$7.00 |
$3,749,998 |
I/I |
535,714 |
2,828,941 |
1.5 |
- |
|
| Gadicke Ansbert |
10% Owner |
– – • |
2011-02-08 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,200,247 |
2,293,227 |
|
- |
|
| Sanderling Venture Partners Vi Co Investment Fund |
10% Owner |
– – • |
2011-02-08 |
4 |
B |
$7.00 |
$1,550,346 |
D/D |
221,478 |
184,131 |
2.45 |
- |
|
| Sanderling Venture Partners Vi Co Investment Fund |
10% Owner |
– – • |
2011-02-08 |
4 |
B |
$7.00 |
$324,653 |
D/D |
46,379 |
46,379 |
2.45 |
- |
|
| Sanderling Venture Partners Vi Co Investment Fund |
10% Owner |
– – • |
2011-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,468,104 |
128,479 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2011-02-08 |
4 |
B |
$7.00 |
$3,749,998 |
D/D |
535,714 |
3,137,597 |
2.45 |
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2011-02-08 |
4 |
A |
$0.00 |
$13,725,237 |
D/D |
2,508,903 |
2,601,883 |
|
- |
|
| Wicki Andreas |
Director |
– • – |
2011-02-08 |
4 |
B |
$7.00 |
$3,749,998 |
I/I |
535,714 |
3,137,597 |
2.1 |
- |
|
| Wicki Andreas |
Director |
– • – |
2011-02-08 |
4 |
A |
$0.00 |
$13,725,237 |
I/I |
2,508,903 |
2,601,883 |
|
- |
|
| Middleton Fred A |
Director |
– • – |
2011-02-08 |
4 |
B |
$7.00 |
$1,874,999 |
I/I |
267,857 |
184,131 |
2.1 |
- |
|
| Middleton Fred A |
Director |
– • – |
2011-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
2,468,104 |
128,479 |
|
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2011-02-08 |
4 |
B |
$7.00 |
$3,749,998 |
I/I |
535,714 |
2,828,941 |
1.5 |
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2011-02-08 |
4 |
A |
$0.00 |
$9,576,900 |
I/I |
2,200,247 |
2,293,227 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2011-02-08 |
4 |
B |
$7.00 |
$3,749,998 |
I/I |
535,714 |
2,828,941 |
2.1 |
- |
|
| Gordon Carl L |
Director |
– • – |
2011-02-08 |
4 |
A |
$0.00 |
$9,576,900 |
I/I |
2,200,247 |
2,293,227 |
|
- |
|
| Gadicke Ansbert |
10% Owner |
– – • |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
92,980 |
|
- |
|
| Wicki Andreas |
Director |
– • – |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
92,980 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
92,980 |
|
- |
|
| Evnin Luke |
Director |
– • • |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
92,980 |
|
- |
|
| Greene William |
10% Owner |
– – • |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
92,980 |
|
- |
|
| Middleton Fred A |
Director |
– • – |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
185,960 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2011-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
92,980 |
|
- |
|
253 Records found
|
|
Page 10 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.34 (1.28%) 
